Skip to main content
ADCT
NYSE Life Sciences

ADC Therapeutics Reports 88.7% ORR in LOTIS-7 and Preliminary Q3 Revenue of $21M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.72
Mkt Cap
$219.588M
52W Low
$0.78
52W High
$4.98
52W Position info
121% above low
Off High info
65% below high
Rel. Volume info
2.6× avg
Market data snapshot near publication time

ADCT has more than doubled off its 52-week low of $0.78 on elevated volume (2.6× avg).

Summary

ADC Therapeutics released updated ASH abstracts showing 88.7% ORR and 75.3% CR for ZYNLONTA plus glofitamab in LOTIS-7, alongside full LOTIS-5 Phase 3 results that met the PFS endpoint but showed a Grade 5 safety imbalance. Preliminary Q3 revenue was $21M with $189.2M of cash as of September 30, 2026.


Key Events · Product Development and Regulatory · ADCT

  • LOTIS-7 Shows 88.7% ORR, 75.3% CR

    Across 97 efficacy-evaluable r/r LBCL patients at the ZYNLONTA 150 µg/kg starting dose plus glofitamab, ORR was 88.7% and CRR 75.3%; 84.9% of complete responders remained in CR at the June 15, 2026 cutoff.

  • MZL IIT: 93% ORR, 90.8% Two-Year PFS

    The Phase 2 investigator-initiated marginal zone lymphoma trial showed 93% ORR and 74.4% CRR among 43 efficacy-evaluable patients, with a two-year PFS rate of 90.8% at a median 23.2 months of follow-up.

  • LOTIS-5 Meets PFS But Grade 5 Imbalance

    Median PFS was 6.14 vs 4.73 months (HR 0.73; P=0.0083), but Grade 5 TEAEs were 13.2% vs 4.6%, driven by infection-related events; the company says the FDA cited benefit-risk concerns and will update on regulatory strategy later.

  • Preliminary Q3 Revenue $21M, Cash $189.2M

    Net product revenue from ZYNLONTA is expected at $21M for Q3 2026 versus $16M a year earlier, with cash of $189.2M at September 30, 2026 and $196M pro forma after the October refinancing; runway is expected into 2029.


Analysis · ADCT · Life Sciences

The LOTIS-7 combination data (88.7% ORR, 75.3% CR, responses still deepening at a median 10.35 months of follow-up) is the strongest efficacy readout in the ZYNLONTA program and the basis for a planned Phase 3 in 2L+ DLBCL, with compendia submission planned for Q1 2027. Against that, the full LOTIS-5 Phase 3 results show the confirmatory trial met its PFS endpoint (6.14 vs 4.73 months, HR 0.73) but carried a Grade 5 safety imbalance of 13.2% vs 4.6%, and the company notes the FDA cited benefit-risk concerns — so the accelerated approval path remains unresolved. Preliminary Q3 net product revenue of $21M and $189.2M of cash (about $196M pro forma for the October PIF refinancing) support a runway into 2029, which buys time for the regulatory strategy to play out.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADCT was trading at $1.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $219.6M. The 52-week trading range was $0.78 to $4.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADCT - Latest Insights

ADCT
Nov 09, 2026, 8:06 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.36 info
Change: -$0.391 (-22%) info
Market Cap: $190.597M info
ADCT
Nov 09, 2026, 7:30 AM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.58
Real-time Price: $1.36 info
Change: -$0.225 (-14%) info
Market Cap: $190.597M info
ADCT
Nov 03, 2026, 5:02 PM EST
Filing Type: S-4
Importance Score:
7
Price at Filing: $1.55
Real-time Price: $1.36 info
Change: -$0.195 (-13%) info
Market Cap: $190.597M info
ADCT
Oct 13, 2026, 6:26 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.82
Real-time Price: $1.36 info
Change: -$0.465 (-26%) info
Market Cap: $190.597M info
ADCT
Oct 08, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.33
Real-time Price: $1.36 info
Change: +$0.025 (+2%) info
Market Cap: $190.597M info